Systemic side effects from topical imiquimod

New Zealand Medical Journal

Volumn 118, Issue 1223, 2005, Pages

  Hanger, H Carl ^a   Dalrymple, Judith ^b   Hepburn, David ^c  

^a PRINCESS MARGARET HOSPITAL   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

^c NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CYANOCOBALAMIN; FERRITIN; HEMOGLOBIN; IMIQUIMOD; AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT;

AGED; ANOREXIA; ARTICLE; BASAL CELL CARCINOMA; BLOOD ANALYSIS; BODY WEIGHT DISORDER; CASE REPORT; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FLU LIKE SYNDROME; HUMAN; MALE; MOOD DISORDER; NIGHT SWEAT; ORTHOSTATIC HYPOTENSION; OUTPATIENT; PATIENT REFERRAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; DEPRESSION; DRUG EFFECT; EATING DISORDER; FACE TUMOR; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BLOOD SEDIMENTATION; CARCINOMA, BASAL CELL; DEPRESSION; EATING DISORDERS; FACIAL NEOPLASMS; FATIGUE; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 27744558991     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Tran H, Moreno G, Shumack S. Imiquimod as a dermatological therapy. Expert Opin Pharmacother. 2004;5:427-38.
2. Goldstein D, Hertzog P, Tomkinson E, et al. Administration of imiquimod, an interferon inducer in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Diseases. 1998;178:858-61.
3. Chen K, Yap LM, Marks R, Shumack S. Short course therapy with imiquimod 5% cream for solar keratoses: a randomised controlled trial. Australasian J Dermatol. 2003;44:250-5.
4. Lipper GM, Arndt KA, Dover JS. Recent Therapeutic advances in Dermatology. JAMA. 2000:283:175-7.
5. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinomas: results from two phase III, randomised, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722-33.
6. Naranjo CA, Busto U. Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics. 1981;30:239-45.
7. Harrison LI, Skinner SL, Marbury TC, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinica keratoses of the face, scalp, or hands and arms. Arch Dermatol Res. 2004;296:6-11.
8. Soria I, Myhre V, Horton P, et al. International J Clin Pharmacol Therap. 2000;10:476-81.
9. Syed TA, Ahmadpour OA, Ahmad SA, Shamsi S. Treatment of genital herpes in males with imiquimod 1% cream. Clin Drug Investigation. 1998;16:187-91.
10. Benson E. Imiquimod: Potential risk of an immunostimulant. Australasian J Dermatol. 2004;45:123-4.
11. Schroecksnadel K, Frick B, Winkler C, et al. Hyperhomocysteinemia and immune activation. Clin Chem Lab Med. 2003;41:1438-43.